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Myelodysplastic Syndromes
Introduction
For more than 20 years the French-American-British mor-
phological classification was the base for the diagnosis of
myelodysplastic syndromes (MDS), a group of acquired clon-
al hematopoietic stem cell disorders with very heteroge-
neous outcomes and characterized by ineffective
hematopoiesis, cytopenias, dysplastic morphological fea-
tures, and an increased risk of development of acute myeloid
leukemia (AML).1,2 In an attempt to improve its prognostic
value, to incorporate other relevant morphological and bio-
logical prognostic characteristics, such as grade of myelodys-
plasia and cytogenetics, and to redefine the border between
MDS and AML, an expert panel of the World Health
Organization (WHO) proposed, in 2001, a new classification
system for MDS3 that was refined in 2008.4 Taking into
account the type and number of cytopenias, percentage of
cells with dysplastic changes in the different myeloid cell lin-
eages, percentage of blasts in peripheral blood and bone mar-
row, percentage of ring sideroblasts in bone marrow,
absolute monocyte count and conventional cytogenetics, the
revised 2008 WHO classification recognizes seven subcate-
gories of MDS that are shown in Table 1 (modified from
Vardiman JW et al.5). Although the usefulness of the WHO
classification was initially criticized,6,7 it has gained wide-
spread acceptance.1,8 The prognostic value of the 2001 WHO
classification is clearly superior to that of the French-
American-British classification9,10 and has been incorporated
into the recently defined WHO classification-based
Prognostic Scoring System (WPSS).11,12 However, the repro-
ducibility of the WHO classification is uncertain. The only
published study on interobserver agreement according to the
2001 WHO criteria showed an acceptable reproducibility.13 A
recent study evidenced a 20% discrepancy in the WHO 2008
classification-based diagnosis between referring and tertiary
care centers.14 The concordance between observers of the
2008 WHO criteria has never been addressed. This issue is
not only academically interesting, but also clinically relevant. 
The aim of this study was to assess the reproducibility of
the WHO 2008 morphological classification. For this purpose
peripheral blood and bone marrow samples from 50 patients
with MDS were blindly and independently reviewed by four
cytomorphologists from three different referral centers with
expertise in the diagnosis of MDS. The interobserver concor-
dance in the quantification of the three morphological char-
acteristics required for the assignment of patients to the
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The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncer-
tain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables
required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples
from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated
using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agree-
ment for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and
erythroid, granulocytic and megakaryocytic dysplastic cells was strong (P<0.001 in all instances). After stratifying
the percentages according to the categories required for the assignment of World Health Organization subtypes,
the degree of agreement was not statistically significant for cases with 5-9% blasts in bone marrow (P=0.07), 0.1-
1% blasts in peripheral blood (P=0.47), or percentage of erythroid dysplastic cells (P=0.49). Finally, the interobserv-
er concordance for World Health Organization-defined subtypes showed a moderate overall agreement (P<0.001),
the reproducibility being lower for cases with refractory anemia with excess of blasts type 1 (P=0.05) and refrac-
tory anemia with ring sideroblasts (P=0.09). In conclusion, the reproducibility of the World Health Organization
2008 classification for myelodysplastic syndromes is acceptable but the defining criteria for blast cells and features
of erythroid dysplasia need to be refined.
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ABSTRACT
appropriate WHO morphological subtype (the number of
blast cells in peripheral blood and bone marrow, percent-
age of ring sideroblasts in bone marrow and myelodys-
plastic features) was evaluated.
Design and Methods
Patients and samples
Samples of bone marrow aspirates and peripheral blood from 50
patients with a clearly established diagnosis of MDS according to
WHO 2008 criteria and diagnosed at two of the participating cen-
ters (Hospital del Mar, Barcelona and Hospital Universitari i
Politecnic La Fe, Valencia) were included in this retrospective
analysis. In all instances the analyzed samples had been obtained
at initial evaluation. The number of cases of the different WHO
2008 morphological subtypes selected for review was prefixed
according to their expected incidence in previous studies.4
Preference for inclusion in the study was given to cases diagnosed
in more recent years and with good quality samples available.
Table 2 summarizes the main characteristics of the patients. 
Morphological studies
Four smears from each patient included in the study were avail-
able for blind and independent microscopical review by four expe-
rienced cytologists from three centers. Two bone marrow and one
peripheral blood May-Grünwald-Giemsa-stained smears were
used for assessing percentages of blasts in peripheral blood and
bone marrow and percentages of dysplastic cells of the three
myeloid cell lines. An additional Prussian blue-stained bone mar-
row smear was used for assessing the percentage of ring siderob-
lasts. The cytologists had a meeting to discuss the evaluation of
dysplasia and diagnosis using training slides. Blasts and ring sider-
oblasts were defined according to the recent consensus proposals
of the International Working Group on Morphology of
Myelodysplastic Syndromes (IWGM-MDS).15 The WHO 2008 rec-
ommendations for evaluating the morphological diagnosis of MDS
were followed strictly. Thus, bone marrow blast counts were cal-
culated as percentages of all bone marrow nucleated cells.
Peripheral blood and bone marrow differential counts were per-
formed on at least 200 and 500 cells, respectively. The evaluation
of dysplasia was based on morphological criteria described in the
2008 WHO publication.4 Briefly, the following morphological fea-
tures of dysplasia were evaluated: (i) dyserythropoiesis: nuclear
budding, internuclear bridging, karyorrhexis, multinuclearity,
nuclear hyperlobation, megaloblastic changes, basophil stippling,
ring sideroblasts and vacuolization; (ii) dysgranulopoiesis: nuclear
hypolobation (pseudo Pelger-Huët), irregular hypersegmentation,
agranularity, pseudo Chediak-Higashi granules, Auer rods and
Döhle bodies; and (iii) dysmegakaryocytopoiesis: micromegakary-
ocytes, nuclear hypolobation, and multinucleation. As defined in
the WHO 2008 classification, the threshold used for considering a
myeloid cell line as dysplastic was the presence of ≥10% abnormal
cells in the corresponding myeloid lineage. To assess dysplasia at
least 200 neutrophils, 200 erythroid precursors and 30 megakary-
ocytes were evaluated in bone marrow. Information on hemoglo-
bin level, and absolute neutrophil and platelet counts was available
for observers when performing the morphological review. In con-
trast, the observers were blinded to the clinical and cytogenetic
data. Consequently, for the purpose of this study, cases of MDS
associated with isolated 5q deletion were classified into other
MDS morphological subtypes. All the morphological characteris-
tics analyzed were recorded in specific forms designed for this pur-
pose by the Spanish Group on Myelodysplastic Syndromes
Table 1. WHO 2008 classification of myelodysplastic syndromes.
Disease Blood findings Bone marrow findings
Cytopenia(s) and others criteria Blasts Dysplasia* and others criteria Blasts
Refractory cytopenias with Uni or  bicytopenia# None or rare (<1%)† Unilineage dysplasia <5%
unilineage dysplasia (RCUD) <15% ring sideroblasts
Refractory anemia (RA) Anemia
Refractory neutropenia (RN) Neutropenia
Refractory thrombocytopenia (RT) Thrombocytopenia
Refractory anemia with ring Anemia None Erythroid dysplasia only <5%
sideroblasts (RARS) ≥15% ring sideroblasts
Refractory cytopenia with Cytopenia(s) None or rare (<1%)† ± 15% ring sideroblasts <5%
multilineage dysplasia (RCMD) <1 x109 monocytes/L No Auer rods No Auer rods
Dysplasia in ≥2 myeloid lineages
Refractory anaemia with excess Cytopenia(s) <5%† Unilineage o multilineage dysplasia 5 – 9%†
blasts-1 (RAEB-1) < 1x109 monocytes/L No Auer rods No Auer rods
Refractory anaemia with excess Cytopenia(s) 5 – 19%‡ Unilineage o multilineage dysplasia 10 – 19%‡
blasts-2 (RAEB-2) < 1x109 monocytes/L ± Auer rods‡ ± Auer rods‡
MDS unclassified (MDS-U) Cytopenia(s) ≤1%† Unequivocal dysplasia in <10% of cells <5%
in ≥1 line when accompanied by 
a cytogenetic abnormality considered 
as presumptive evidence for a diagnosis 
of MDS$
MDS  associated with isolated Anemia None or rare (<1%) Normal to increased megakaryocytes <5%
del(5q) Usually normal or increased with hypolobated nuclei No Auer rods
platelet count Isolated del(5q) abnormality
*The percentage of cells manifesting dysplasia required to qualify as significant is ≥10% for each myeloid lineage. #Bicytopenia may occasionally be observed. Cases with pancytopenia
should be classified as MDS-U. †If the marrow myeloblast percentage is <5% but there are 2-4% myeloblasts in the blood, the diagnosis is RAEB1. Cases of RCUD and RCMD with myeloblasts
in the blood should be classified as MDS-U. ‡Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB2.  $A presumptive diagnosis of
MDS may be made in the absence of dysplasia if any of the following cytogenetic abnormalities is present: a) unbalanced: -7 or del(7q), -5 or del(5q), i(17q) or t(17p), -13 or del(13q),
del(11q), del(12p) or t(12p), del(9q) and idic(X)(q13); b) balanced: t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(2;11)(p21;q23), inv(3)(q21q26.2) and t(6;9)(p23;q34). 
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Table 2. Main characteristics of the patients.
Patient Date of diagnosis Gender Age WHO classification* Karyotype IPSS risk 
cathegory
1 28-01-09 M 82 RCUD 47,XY,+18[1]46,XY[19] Int-1
2 10-12-07 F 77 RARS 46,XX[20] Low
3 15-01-08 M 76 RARS 46,XY[16] Low
4 01-07-07 M 81 RCUD 46,XY[20] Low
5 24-03-09 M 59 RCDM 46,XY[20] Low
6 12-12-07 M 67 RCDM 46,XY[20] Int-1
7 11-06-09 M 76 RCDM 46,XY[23] Int-1
8 10-09-09 F 54 RAEB-1 46,XX[14] Int-1
9 22-09-11 F 65 RAEB-1 41-43,XX,der(2)?ins(2;?)(q11.2;?),t(4;7)(q33-35;q11.2),
del(5)(?q22),del(7)(q22),del(9)(q22q34),add(11)
(p15),-12,-13,-17,-21,+2mar[cp16]/46,XX,del(11)(q23)
[5]/46,XX[4] High
10 01-04-09 F 47 RAEB-1 45,XX-7[14]/46,sl,+8[1]/46,XX[9] High
11 17-10-06 F 55 RAEB-2 45,XX-7[1] High
12 09-05-08 M 89 RCUD 46,XY[16] Low
13 20-10-09 F 80 RAEB-2 46,XX[20] High
14 27-07-10 F 84 RARS 46,XX[20] Low
15 19-08-09 M 67 RAEB-1 47,XY,+13[6]/46,XY[12] Int-2
16 28-05-09 M 82 RAEB-1 46,XY[20] Int-2
17 14-04-10 F 56 RCDM 46,XX[20] Low
18 31-03-10 F 46 RCDM 47,XX+8[2]/46,XX[18] Int-1
19 28-09-09 M 77 RCDM 46,XY[20] Low
20 25-05-10 M 77 RCDM 46,XY[20] Low
21 29-06-09 F 46 RAEB-2 46,XX-7[12]/46,XX[8] High
22 02-12-04 F 58 RAEB-2 46,XX, der(1), (q21;q44), +8, del[11](q21)[20] High
23 24-01-11 F 53 RAEB-2 46,XX[20] High
24 18-05-10 F 79 MDS-U 47,XX,+8[3]/46,XX[7] Int-2
25 24-06-02 M 77 RAEB-1 46,XY[10] Int-1
26 21-10-09 F 75 RARS 46,XX[20] Low
27 13-07-09 F 80 RCDM 47,XX,+8[13]46,XX[7] Int-1
28 15-07-09 M 82 RAEB-1 46,XY,del(7q)[16]46,XY[4] Int-2
29 12-12-07 M 73 RAEB-1 46,XY[15] Int-2
30 02-06-08 M 82 MDS-U 45,X,-Y[11]46,XY[9] Low
31 12-06-08 M 82 RCUD 46,XY[20] Low
32 21-05-03 F 81 RCUD 46,XX[20] Low
33 20-08-08 M 70 RAEB-1 46,XY[20] Int-1
34 24-08-09 M 81 RCDM 46,XY[20] Int-2
35 27-10-08 F 58 RARS 46,XX[20] Low
36 04-12-02 M 73 RAEB-1 46,XY[4] Int-1
37 02-06-09 M 76 RAEB-2 46,XY[20] Low
38 20-02-08 F 82 5q- MDS 46,XX,del(5q)[14]46,XX[6] Low
39 14-09-09 M 89 RCDM 47,XY,+mar[8] Int-1
40 27-06-05 M 75 RAEB-1 46,XY[20] Int-1
41 07-02-07 F 67 RCUD 46,XX[20] Low
42 19-01-09 M 80 RCDM 45,X,-Y[20] Low
43 29-10-08 F 75 RAEB-2 46,XX[14] Int-2
44 21-04-08 F 78 RARS 46,XX[20] Low
45 13-10-08 M 60 RAEB-2 46,XY[20] Int-2
46 04-12-06 M 68 RAEB-1 46,XY[20] Int-1
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(GESMD) and transferred into a specific database. Once the review
had been finished, no attempt was made to reach a consensus
agreement on cases with discrepant results in any of the variables
analyzed. The local ethics committees approved the studies which
were conducted in accordance with the 2000 revision of the
Helsinki Declaration.
Statistical analysis
Agreement between the four observers for continuous quantita-
tive variables (percentages of blasts in peripheral blood and bone
marrow, percentages of ring sideroblasts in bone marrow and per-
centages of dysplastic cells of erythroid, granulocytic and
megakaryocytic lineages) was evaluated using the intraclass corre-
lation coefficient (ICC).16 The ICC has advantages over Spearman’s
correlation coefficient, because it is adjusted for the effects of the
scale of measurements, and allows the assessment of agreement
when there are more than two observers. Quantitative variables
(percentages of blast cells in peripheral blood and bone marrow,
percentages of ring sideroblasts in bone marrow and percentage of
dysplastic cells in each myeloid lineage) were categorized and also
evaluated as categorical variables (Table 3). For this purpose, we
used the cutoff levels defined by the WHO classification and an
additional cutoff level of 40% of dysplastic cells according to pre-
vious data.17 To evaluate the concordance between observers in
qualitative and categorized quantitative variables, the generalized
kappa statistic for multiple raters (κ) was calculated. An ICC or
generalized κ statistic value of 1 denotes complete agreement
between the different observers, while an ICC value of 0 denotes
agreement equivalent to chance. Both the ICC and the generalized
κ statistic can be interpreted as follows: 0-0.2 indicates poor
agreement, 0.3-0.4 indicates fair agreement, 0.5-0.6 indicates
moderate agreement; 0.7-0.8 indicates strong agreement, and >0.8
indicates almost perfect agreement.18 The statistical package SPSS,
version 19.0 (SPSS Inc., Chicago, IL, USA) was used to calculate the
ICC and a Microsoft Excel Template to calculate the κ statistic.
Results
The degree of concordance between observers for the
different morphological characteristics is summarized in
Table 3.
Interobserver concordance regarding blast cell count
There was a strong agreement in the percentage of blast
cells in bone marrow considered as a continuous variable.
The ICC for this parameter was 0.95 [95% confidence
interval (CI), 0.92-0.97; P<0.001)]. When its degree of
concordance was assessed stratifying the variable into three
categories (<5%, 5-9%, and ≥10%), according to the
thresholds used in WHO classification subtypes, the
interobserver concordance was moderate (overall κ, 0.57;
P<0.001). The degree of agreement was higher and
significant when the bone marrow blast percentage was
less than 5% (κ, 0.72; P<0.001) or equal or greater to 10%
(κ, 0.65; P<0.001), but it was lower for cases with an
intermediate percentage of bone marrow blast cells (5-9%)
for which only a fair agreement was reached (κ, 0.29;
P=0.07). When this variable was further stratified into four
categories, adding a cutoff point of 2% blast cells in bone
marrow, the interobserver concordance was fair (overall κ
0.42; P<0.001). The κ values were 0.50 (P=0.002) for cases
with less or equal to 2%, 0.28 (P=0.065) for cases with more
than 2% and less than 5%, 0.29 (P=0.048) for cases with
5% to less than 10% and 0.60 (P<0.001) for cases with
more or equal than 10%. 
Interobserver agreement for the percentage of blast cells
in peripheral blood showed a very good agreement. The
ICC for this parameter was 0.82 (95% CI: 0.72-0.89). When
the variable was evaluated according to the subcategories
used in the WHO classification (absent, less or equal to 1%
and more than 1%), the overall kappa score was 0.30
(P<0.002). The agreement between observers was
significant in the condition with more than 1% blasts (κ,
0.37; P=0.009), but there was no significant agreement
between observers in the condition without blasts (κ, 0.37;
P=0.20) and in the intermediate category of less than or
equal to 1% blasts (κ, 0.09; P=0.47).
Interobserver concordance regarding ring 
sideroblast count
The agreement between observers on the percentage of
ring sideroblasts in bone marrow was nearly perfect
analyzed both as a continuous variable (ICC, 0.96; 95% CI:
0.93-0.98; P<0.001) and with the 15% cutoff point used in
the WHO criteria (κ, 0.82; P<0.001).
Interobserver concordance regarding the assessment 
of dysplasia
When the degree of dysplasia of the three different
hematopoietic cell lines was studied as a continuous
variable, the degree of concordance between observers was
strong and almost perfect for the megakaryocytic lineage
with an ICC of 0.91 (95% CI: 0.85-0.95; P<0.001) and for
the granulocytic lineage with an ICC of 0.89 (95% CI: 0.83-
0.94; P<0.001). A substantial agreement was observed for
the erythroid lineage with an ICC of 0.75 (95% CI: 0.60-
0.85; P<0.001). When those variables were stratified
according to the 10% cutoff point required by the WHO
criteria to define a hematopoietic cell lineage as dysplastic,
the interobserver agreement was statistically significant for
the granulocytic (κ, 0.40; P=0.04) and megakaryocytic (κ,
0.49; P<0.001) lineages. There was poor agreement
regarding the erythroid lineage (κ, 0.19; P=0.49). When a
cutoff of 40% dysplastic cells was used, the concordance
between raters improved for the megakaryocytic and
granulocytic lineages but did not improve for the erythroid
lineage.
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47 15-10-08 M 82 RCDM 46,XY[20] Low
48 08-10-08 M 70 RCDM 46,XY[20] Int-1
49 22-04-09 M 83 RCDM 46,XY[20] Low
50 03-06-09 M 79 RCDM 46,XY[20] Int-1
M: male; F: female; RCUD: refractory cytopenia with unilineage dysplasia; RARS: refractory anemia with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia;
RAEB: refractory anemia with excess of blasts; MDS-U: myelodysplastic syndrome unclassified; 5q- MDS: MDS associated with isolated del(5q); IPSS: International Prognostic Scoring
System; Int-1: Intermediate-1; Int-2: Intermediate-2. * WHO 2008 diagnosis previously established by the center of origin.
Continued from the previous page
Reproducibility of World Health Organization-defined
subtypes of myelodysplastic syndromes  
The overall interobserver concordance for WHO-defined
MDS subtypes showed a moderate overall agreement (κ,
0.43; P<0.001) (Table 3 and Figure 1). A greater
reproducibility was found for patients with refractory
anemia with excess blasts-2 (κ, 0.60, P<0.001), refractory
cytopenias with unilineage dysplasia (κ, 0.5; P<0.001) and
refractory cytopenia with multilineage dyplasia (κ, 0.46;
P<0.01). Concordance was lower for refractory anemia
with ring sideroblasts (κ, 0.26, P=0.09) and refractory
anemia with excess blasts-1 (κ, 0.29; P=0.05). 
Discussion
Despite major advances in the diagnosis of hematologic
diseases, cytomorphological criteria remain the cornerstone
of the diagnosis of MDS. The current study was designed
to evaluate interobserver variability in assigning a diagnosis
of MDS according to the WHO 2008 classification criteria
and to define potential morphological difficulties. In our
study, we observed a moderate reproducibility of the WHO
2008 classification.
In 2008, Muffi et al.15 pointed out the difficulty of
morphological diagnosis of blast cells, although the
percentage of blasts in bone marrow is one of the main
known prognostic factors7,19-20 and has been included in the
most commonly used prognostic scoring systems for MDS,
such as the International Prognostic Scoring System (IPSS)
and the WHO classification-based Prognostic Socring
System (WPSS). In our work we found an almost perfect
agreement regarding bone marrow blast cell count in cases
with <5% or with ≥10%. In those cases with a blast cell
count ≥5% and <10%, the rate of concordance showed a
moderate agreement. This implies that one patient could be
classified as having refractory cytopenia with multilineage
dysplasia, refractory anemia with excess blasts-1 or
refractory anemia with excess blasts-2 depending on the
observer. We decided to evaluate the interobserver
concordance for an additional cutoff point of 2% blasts in
bone marrow for cases without excess of blasts because this
threshold seems to portray prognostic relevance in the
revised version of the IPSS21. The degree of agreement was
adequate for cases with ≤2% blast cells but, again, it was not
as good for cases with blast cell counts between 2% and
5%. Discrepancies in the blast count in bone marrow of
patients with myeloid malignancies, including MDS, is
partly due to the difficulty in distinguishing between
granular blast cells and promyelocytes and the irregular
distribution of blast cells in bone marrow. Although a good
correlation between the percentage of blasts determined by
morphological examination and percentage of CD34+ cells
determined by flow cytometry is usually observed, blast
enumeration by morphology is the gold-standard method.4,22
The correct assignment of the percentage of blasts in
peripheral blood is also crucial for a correct diagnosis
and classification of patients.23 In our study, we found a
fair agreement in peripheral blood blast cell count. This
result may be due to the low level of blast cells present
in peripheral blood. Interobserver discrepancies may
best be resolved by increasing the number of cells in the
differential counts.
The recognition of dysplastic signs has a crucial value not
only for the diagnosis and classification of MDS patients,
but also has a prognostic role in low-risk MDS patients. In
this regard, Pseudo-Pelger-Huët anomaly in neutrophils and
micromegakaryocytes has been correlated with overall
survival.17,24 Besides, several investigators consider that cases
with multilineage dysplasia have a less favorable prognosis
than those with only dyserythropoietic dysplasia.10,25-26 The
WHO classification therefore separated cases with
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Table 3. Statistical analyses of interobserver degree of agreement
regarding morphological features.
κ (P value) κ (P value) ICC
Blasts in peripheral blood (%) 
0 0.37 (P=0.204)
≤1 0.09 (P=0.479)
>1 0.37 (P=0.009)
Overall kappa 0.30 (P=0.002)
As a continuous variable 0.82
Blasts in bone marrow (%)
Percentage Percentage
≤2 0.50 (P=0.002)
>2  to <5 0.28 (P=0.065) <5 0.72 (P<0.001)
5-9 0.29 (P=0.048) 5-9 0.26 (P=0.071)
≥10 0.60 (P<0.001) ≥10 0.65 (P<0.001)
Overall 0.42 (P<0.001) Overall 0.57 (P<0.001)
As a continuous variable 0.95
Bone marrow ring sideroblasts (%)
Percentage
<15                       0.82
≥15                       0.82
Overall 0.82 (P<0-001)
As a continuous variable 0.96
Bone marrow granulocytic dysplasia (%)
Percentage Percentage
<10 0.39  (P=0.009) <10 0.40 (P=0.009)
10-39 0.32 (P=0.06) >10 0.40 (P=0.43)
≥40 0.50 (P=0.04)
Overall  0.41 (P<0.001) Overall 0.40 (P=0.04)
As a continuous variable 0.89
Bone marrow megakaryocytic dysplasia (%)
Percentage Percentage
<10 0.49 (P=0.004) <10 0.49 (P=0.004)
10-39 0.22 (P=0.21) >10 0.49 (P=0.12)
≥40 0.56 (P=0.005)
Overall 0.43 (P<0.001) Overall 0.49 (P<0.001)
As a continuous variable 0.91
Bone marrow erythroid dysplasia (%)
Percentage Percentage
<10 0.19 (P=0.21) <10 0.19 (P=0.21)
10-39 0.04 (P=0.83) >10 0.19 (P=0.78)
≥40 0.15 (P=0.47)
Overall 0.11 (P=0.08) Overall 0.19 (P=0.49)
As a continuous variable 0.75
WHO 2008 subtype
RCUD 0.51(P<0.001)
RARS 0.26(P=0.09)
RCMD 0.46(P=0.01)
RAEB-1 0.29 (P=0.05)
RAEB-2 0.60 (P<0.001)
MDS-U 0.01 (P=0.97)
Overall 0.43 (P<0.001)
ICC: intraclass correlation coefficient; κ: generalized kappa statistic for multiple raters;
RCUD: refractory cytopenia with unilineage dysplasia; RARS: refractory anemia with
ring sideroblasts; RCMD: refractory anemia with multilineage dysplasia; RAEB-1:
refractory anemia with excess blasts-1; RAEB-2: refractory anemia with excess blasts-2;
MDS-U: myelodysplastic syndrome-unclassified.
refractory anemia in the previous French-American-British
classification into two categories depending on the presence
or absence of multilineage dysplastic features. This
distinction has been criticized by some groups,6,7 because
the assessment of the features of dysplasia is not always
easy in clinical practice because of the lack of definition of
objective parameters. Poor technical quality of the
specimen could also be an obstacle to an accurate diagnosis
of dysplasia. In our work we found a moderate but
significant interobserver agreement for megakaryocytic and
granulocytic dysplasia and a poor agreement for erythroid
dysplasia. This is probably because features of
dysgranulopoiesis (pseudo-Pelger-Huët, hypogranularity)
and dysmegakaryopoiesis (micromegakaryocytes, non-
lobulated nuclei and multiple widely separated nuclei) are
less subjective and more reproducible than features of
erythroid dysplasia. 
The WHO classification includes a uniform threshold of
10% for dysplasia in each myeloid lineage; however, as
discussed by Parmentier et al.,27 this level of dysplasia is
highly questionable and is particularly low in the
megakaryocytic lineage in which the number of cells
analyzed is smaller than in the other series. We analyzed
the interobserver concordance with a cutoff point of 40%
dysplastic cells and found that the agreement improved in
the megakaryocytic and granulocytic lineages but not in the
erythroid lineage. These results agree with those of
Matsuda et al.17 and Germing et al.28 who proposed raising
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Figure 2. Evaluation of dysplastic
features in erythropoiesis such as
megaloblastoid changes (arrows)
and cytoplasmic changes (disconti-
nous arrow) is poorly reproducible
explaining why the agreement
between observers in the evaluation
of dyserythropoiesis is not good.
Figure 1. The presence of granulated
blast cells (arrows) makes the distinc-
tion between blast cells and promyelo-
cytes (discontinous arrow) difficult so
that the number of  blast cells may dif-
fer and the same patient may be clas-
sified as having MDS with or without
excess of blasts.
the threshold of dysmegakaryopoiesis from 10 to 40%.
The prognostic value of the WHO classification is already
known.7,9,10,12 Howe et al.13 analyzed the reproducibility of
the 2001 WHO classification showing a 92% of agreement
among three reviewers. Their discrepancies were related to
the identification and enumeration of dyspoiesis in
neutrophils and megakaryocytes and in those cases with
borderline blast percentages. 
Recently, Naqvi et al.14 analyzed the discrepancies in
morphological diagnosis of MDS between referral and
tertiary centers showing differences in 12% of the patients.
They did not, however, analyze the causes of the
discrepancy.
The current work, although reviewing a rather limited
number of samples, is the first to analyze the correlation
between observers of the 2008 WHO morphological
criteria. We found a nearly moderate and significant
concordance regarding the definition of 2008 WHO MDS
subtypes (κ, 0.43; P<0.001). Most differences concerned the
distinction of unilineage and multilineage dysplasia;
consequently some patients were classified as having
refractory anemia with ring sideroblasts or refractory
cytopenia with multilineage dysplasia depending on the
recognition of dysplasia in one or more myeloid lineages.
As previously described by Howe et al.,13 we also had
difficulties in assigning MDS subtypes in those cases with
borderline blast cell percentages. In fact, a substantial
agreement was obtained only in cases with less than 2% or
more than 10% of blast cells in the bone marrow.
To sum up, the WHO 2008 classification can be applied
with a moderate interobserver concordance.
Discrepancies are frequent and may have a potential
negative impact on the assignment of prognosis and
therapy planning in the individual patient. The degree of
agreement could be improved if the criteria for features for
dyserythropoiesis were to be refined. Future studies
should evaluate the potential increment in the threshold
for considering a cell lineage as dysplastic in order to
enhance the recognition of multilineage dysplasia. Finally,
the diagnosis of MDS is complex, requires an accurate
application of the WHO criteria, and should be performed
by experienced morphologists. Despite all those
measures, it must be highlighted that the value of
cytomorphology alone for the classification of MDS is
limited. In this regard, the development, standardization,
and incorporation into our daily practice of other
techniques, such as flow cytometry and molecular
studies,29-31 will likely allow us to diagnose, characterize,
and classify this heterogeneous group of myeloid
neoplasms better in the near future.
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